Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RHAMM marks proliferative subpopulation of human colorectal cancer stem cells.
Nakano M, Taguchi R, Kikushige Y, Isobe T, Miyawaki K, Mizuno S, Tsuruta N, Hanamura F, Yamaguchi K, Yamauchi T, Ariyama H, Kusaba H, Nakamura M, Maeda T, Kuo CJ, Baba E, Akashi K. Nakano M, et al. Among authors: akashi k. Cancer Sci. 2023 Jul;114(7):2895-2906. doi: 10.1111/cas.15795. Epub 2023 Mar 31. Cancer Sci. 2023. PMID: 36945114 Free PMC article.
Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y, Uchida N, Wake A, Miyawaki K, Eto T, Nakamura T, Iwasaki H, Ito Y, Tanimoto K, Katayama Y, Imamura Y, Takahashi T, Fujisaki T, Kamimura T, Choi I, Ishitsuka K, Yoshimoto G, Ogawa R, Sugita J, Takamatsu Y, Tanimoto K, Hidaka T, Miyamoto T, Akashi K, Nagafuji K. Mori Y, et al. Among authors: akashi k. Vaccine. 2023 Nov 13;41(47):6899-6903. doi: 10.1016/j.vaccine.2023.08.066. Epub 2023 Oct 20. Vaccine. 2023. PMID: 37866994
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.
Uehara K, Tanoue K, Yamaguchi K, Ohmura H, Ito M, Matsushita Y, Tsuchihashi K, Tamura S, Shimokawa H, Isobe T, Shibata Y, Ariyama H, Tanaka R, Kusaba H, Yamamoto H, Oda Y, Akashi K, Baba E. Uehara K, et al. Among authors: akashi k. Cancer Immunol Immunother. 2023 Nov;72(11):3543-3558. doi: 10.1007/s00262-023-03505-4. Epub 2023 Aug 7. Cancer Immunol Immunother. 2023. PMID: 37550428 Free PMC article.
A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K, Fujii N, Makita S, Goto H, Kanda J, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Nakamura S, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. Kato K, et al. Among authors: akashi k. Int J Hematol. 2023 Mar;117(3):409-420. doi: 10.1007/s12185-022-03494-7. Epub 2022 Nov 18. Int J Hematol. 2023. PMID: 36399286 Clinical Trial.
Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
Tani N, Ikematsu H, Goto T, Kondo S, Gondo K, Fujiyoshi N, Minami J, Harada Y, Nagano S, Horiuchi T, Kuwano H, Akashi K, Shimono N, Chong Y. Tani N, et al. Among authors: akashi k. Vaccine. 2023 Oct 26;41(45):6672-6678. doi: 10.1016/j.vaccine.2023.09.051. Epub 2023 Sep 27. Vaccine. 2023. PMID: 37775465 Free article.
957 results